- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 13.06. | AlzeCure Pharma: New Scientific Article Published on Positive Clinical Results with Painless ACD440 Against Neuropathic Pain | 265 | ACCESSWIRE | STOCKHOLM, SWEDEN / ACCESSWIRE / June 13, 2024 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical company that develops candidate drugs for diseases... ► Artikel lesen | |
| 28.05. | Nasdaq Stockholm AB: New last day of trading in paid subscription shares (BTA) of AlzeCure Pharma AB (publ) | 155 | GlobeNewswire | At the request of AlzeCure Pharma AB (publ), the last trading day in AlzeCure
Pharma AB (publ)'s paid subscription units will be changed from May 30, 2024 to
May 31, 2024.
Short name: ALZCUR BTA... ► Artikel lesen | |
| 24.05. | Führungsentscheidungen bei TÜV Nord, KSB, Lanzajet, Alzecure und Movianto | 24 | PROCESS | ||
| 15.05. | AlzeCure Pharma: Eli Lilly's and AstraZeneca's Former Head of Research Dr. Jan Lundberg Elected as a New Board Member | 454 | ACCESSWIRE | STOCKHOLM, SWEDEN / ACCESSWIRE / May 15, 2024 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB, a pharmaceutical company that develops candidate drugs for CNS diseases, focusing on Alzheimer's... ► Artikel lesen | |
| 14.05. | Communiqué from the Annual General Meeting of AlzeCure Pharma on 14 May 2024 | 501 | ACCESSWIRE | STOCKHOLM, SWEDEN / ACCESSWIRE / May 14, 2024 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) Today, 14 May 2024, the annual general meeting was held in AlzeCure Pharma AB (publ) (the "Company"). Below is a... ► Artikel lesen | |
| 13.05. | AlzeCure Pharma: AlzeCure Reports Anti-Inflammatory Effects with NeuroRestore ACD856 with Relevance to Alzheimer's Leading to New Patent Application | 209 | ACCESSWIRE | STOCKHOLM, SWEDEN / ACCESSWIRE / May 13, 2024 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical company that develops candidate drugs for diseases affecting... ► Artikel lesen | |
| 30.04. | Nasdaq Stockholm AB: Listing of subscription rights and paid subscription shares of AlzeCure Pharma AB | 280 | GlobeNewswire | With effect from May 02, 2024, the subscription rights in AlzeCure Pharma AB
will be traded on First North Growth Market. Trading will continue up until and
including May 14, 2024.
Instrument: Subscription... ► Artikel lesen | |
| 25.04. | AlzeCure Pharma: AlzeCure Publishes its Interim Report for January - March 2024 | 587 | ACCESSWIRE | STOCKHOLM, SWEDEN / ACCESSWIRE / April 25, 2024 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO:ALZCUR) today announced that its interim report for the period January - March... ► Artikel lesen | |
| 25.04. | XFRA CAPITAL ADJUSTMENT INFORMATION - 25.04.2024 | 218 | Xetra Newsboard | Das Instrument AB2 NL0011540547 ABN AMRO BANK DR/EO1 EQUITY wird cum Kapitalmassnahme gehandelt am 25.04.2024 und ex Kapitalmassnahme am 26.04.2024 The instrument AB2 NL0011540547 ABN AMRO BANK DR/EO1... ► Artikel lesen | |
| 10.04. | AlzeCure Pharma: Eli Lilly's and AstraZeneca's Former Head of Research Dr. Jan Lundberg Invests in AlzeCure and is Proposed for Election to its Board | 2.335 | ACCESSWIRE | STOCKHOLM, SWEDEN / ACCESSWIRE / April 10, 2024 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB ("AlzeCure" or "the Company"), a pharmaceutical company that develops candidate drugs for CNS... ► Artikel lesen | |
| 04.04. | AlzeCure Pharma Publishes its Annual Report for 2023 | 229 | ACCESSWIRE | STOCKHOLM, SE / ACCESSWIRE / April 4, 2024 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical company that develops a broad portfolio of small molecule... ► Artikel lesen | |
| 03.04. | AlzeCure Pharma: AlzeCure Presents New Data Regarding the TrkA-NAM Pain Project at IASP 2024 | 249 | ACCESSWIRE | STOCKHOLM, SWEDEN / ACCESSWIRE / April 3, 2024 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical company that develops candidate drugs for CNS diseases... ► Artikel lesen | |
| 14.03. | AlzeCure Pharma: AlzeCure to Partake in Redeye Theme: Alzheimer on March 21 | 279 | ACCESSWIRE | STOCKHOLM, SWEDEN / ACCESSWIRE / March 14, 2024 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical company that develops small molecule drug candidates... ► Artikel lesen | |
| 07.03. | AlzeCure Pharma: AlzeCure Presents New Preclinical Data with NeuroRestore ACD856 at Leading Alzheimer's Conference | 586 | ACCESSWIRE | STOCKHOLM, SWEDEN / ACCESSWIRE / March 7, 2024 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company that develops small molecule drug candidates... ► Artikel lesen | |
| 05.03. | AlzeCure Pharma: AlzeCure Publishes Clinical Results Supporting Continued Development of NeuroRestore ACD856 Against Alzheimer's | 429 | ACCESSWIRE | STOCKHOLM, SWEDEN / ACCESSWIRE / March 5, 2024 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical company that develops small molecule drug candidates... ► Artikel lesen | |
| 29.02. | AlzeCure Pharma: AlzeCure's Alzheimer's Project NeuroRestore ACD856 is Granted an Additional Patent | 389 | ACCESSWIRE | STOCKHOLM, SWEDEN / ACCESSWIRE / February 29, 2024 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company that develops candidate drugs for CNS... ► Artikel lesen | |
| 27.02. | AlzeCure Pharma: AlzeCure Publishes its Year-end Report for January - December 2023 | 339 | ACCESSWIRE | STOCKHOLM, SWEDEN / ACCESSWIRE / February 27, 2024 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO:ALZCUR) today announced that its Year-end report for the period January -... ► Artikel lesen | |
| 12.02. | AlzeCure Pharma Broadcasts Live Expert Event on Alzheimer's Around Highly Current Gamma-Secretase Modulators | 284 | ACCESSWIRE | STOCKHOLM, SE / ACCESSWIRE / February 12, 2024 / AlzeCure Pharma (STO:ALZCUR) (FRA:AC6) AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company that develops candidate drugs for CNS diseases... ► Artikel lesen | |
| 06.02. | AlzeCure Pharma: AlzeCure Gets Late Breaking Abstract of New Preclinical Data with ACD856 Accepted at AD/PD 2024 Conference | 953 | ACCESSWIRE | STOCKHOLM, SWEDEN / ACCESSWIRE / February 6, 2024 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company that develops candidate drugs for CNS diseases... ► Artikel lesen | |
| 31.01. | AlzeCure Pharma: AlzeCure CEO Martin Jönsson to Present at the International Investor Conference BioCapitalEurope | 571 | ACCESSWIRE | STOCKHOLM, SWEDEN / ACCESSWIRE / January 31, 2024 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical company that develops candidate drugs for CNS diseases... ► Artikel lesen |
Seite:
1 2 Weiter >>
38 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| VERTEX PHARMACEUTICALS | 458,75 | +0,54 % | Is Vertex Pharmaceuticals' Monopoly in Danger? | ||
| VIATRIS | 11,150 | +0,18 % | Kursgewinne für die Viatris-Aktie (11,0505 €) | Am US-amerikanischen Aktienmarkt notiert die Aktie von Viatris derzeit ein wenig fester. Der jüngste Kurs betrug 12,00 US-Dollar. Ein Kursplus in Höhe von 24 Cent erfreut derzeit die Aktionäre von Viatris.... ► Artikel lesen | |
| OPKO HEALTH | 1,287 | +2,96 % | OPKO Health, Inc.: OPKO Health Reports First Quarter 2024 Business Highlights and Financial Results | MIAMI, May 07, 2024 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three months ended March 31, 2024. First quarter business highlights... ► Artikel lesen | |
| JAGUAR HEALTH | 1,280 | -5,19 % | Jaguar Health Reports Phase 3 OnTarget Trial Results for its Cancer Supportive Care Drug Crofelemer | Initial results of unprecedented trial including 10 different tumor types indicate that OnTarget did not meet its primary endpoint across all tumor types. Trial did reveal clinically relevant signals... ► Artikel lesen | |
| ALTIMMUNE | 6,215 | +0,05 % | Altimmune, Inc: Altimmune Announces Publication of Clinical Study of Pemvidutide in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in Journal of Hepatology | ||
| SELLAS LIFE SCIENCES | 1,088 | +1,30 % | SELLAS Life Sciences Group, Inc.: SELLAS Announces U.S. FDA Rare Pediatric Disease Designation (RPDD) Granted to SLS009 for the Treatment of Pediatric Acute Myeloid Leukemia | - Acute Myeloid Leukemia (AML) is the Second Most Common Hematological Malignancy in Children Often Associated with Poorer Prognosis Compared to Other Pediatric Cancers - - This Recognition Marks... ► Artikel lesen | |
| AURINIA PHARMACEUTICALS | 5,028 | -0,12 % | ILJIN SNT Co., Ltd. Announces Its Intention to Vote Against Aurinia Pharmaceuticals's Revised Equity Incentive Plan Proposal | SEOUL, South Korea, June 7, 2024 /PRNewswire/ --
Dear Fellow Shareholders,
ILJIN SNT Co., Ltd. ("ILJIN") is a long-standing investor of Aurinia Pharmaceuticals Inc. ("Aurinia" or... ► Artikel lesen | |
| DMK PHARMACEUTICALS | 2,900 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 13.02.2024 - 2 | The following instruments on Boerse Frankfurt do have their last trading day on 13.02.2024Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 13.02.2024ISIN NameLU0102219945 G.SACHS... ► Artikel lesen | |
| KIORA PHARMACEUTICALS | 0,430 | 0,00 % | Kiora Pharmaceuticals, Inc.: Kiora Pharmaceuticals to Participate in Jones Healthcare Seaside Summit 2024; Kiora Invites Investors to Submit Questions Following the Conference Presentation | Encinitas, California--(Newsfile Corp. - July 10, 2024) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) (KPRX) ("Kiora" or the "Company"), today announced that Eric Daniels, M.D., Chief Development Officer... ► Artikel lesen | |
| LIPOCINE | 5,570 | -4,30 % | Lipocine Inc.: Lipocine Presents 52 Week Results from LPCN 1148 Phase 2 Study in Late Breaking Session at EASL Congress 2024 | SALT LAKE CITY, June 10, 2024 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company, today announced that Phase 2 results on LPCN 1148 in cirrhosis were featured in a late breaking... ► Artikel lesen | |
| PHOTOCURE | 4,470 | +1,71 % | Photocure and Richard Wolf Enter into Agreement to Develop a High-Definition Flexible Blue Light Cystoscope for Global Commercialization | OSLO, Norway, July 15, 2024 /PRNewswire/ -- Photocure ASA (OSE: PHO), the Bladder Cancer Company, today announces that it has entered into a strategic agreement with Richard Wolf GmbH to... ► Artikel lesen | |
| ACLARIS THERAPEUTICS | 1,293 | +0,58 % | Aclaris Therapeutics And 3 Other Stocks Under $2 Insiders Are Buying | ||
| SOLID BIOSCIENCES | 9,310 | +2,87 % | Solid Biosciences Inc.: Solid Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | CHARLESTOWN, Mass., July 01, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the "Company"), a life sciences company developing precision genetic medicines for neuromuscular and cardiac... ► Artikel lesen | |
| EUROBIO SCIENTIFIC | 16,720 | -0,48 % | Eurobio Scientific: Fiscal Year 2023, Strategic Transformation Of The Group | FISCAL YEAR 2023, STRATEGIC TRANSFORMATION OF THE GROUP Continued total year growth in core business revenues, up 39%Successful deployment of the Group's strategy: Proprietary products up at 30% of... ► Artikel lesen | |
| MEDICURE | 0,755 | 0,00 % | Medicure, Inc.: Medicure Announces Signing of Asset Purchase Agreement with CanAm Bioresearch Inc. for Acquisition of Intellectual Property | WINNIPEG, MB / ACCESSWIRE / June 24, 2024 / Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH)(OTC PINK:MCUJF), a company focused on the development and commercialization of pharmaceuticals and... ► Artikel lesen |
ALZECURE PHARMA AB gehört der Branche Pharma an. Der aktuelle Kurs liegt bei 0,140 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ALZECURE PHARMA AB finden Sie auf Wallstreet Online.
